Cardionovum

Be up
to date.

Latest press release

Cardionovum® announces that the XLIMIT Trial results, featuring the XLIMUS® DES, have been published online in the Frontiers in Cardiovascular Medicine journal with the article entitled “A randomized control trial to assess optical coherence tomography parameters of the Xlimus drug-eluting stent: the XLIMIT trial”.

 

XLIMIT is a non-inferiority, prospective, multicenter, randomized, controlled trial in which a total of 177 patients were enrolled and randomized in two groups in a 2:1 ratio (2 XLIMUS®:1 Synergy™).

The primary endpoint of this study has been defined as the in-stent neointimal volume weighted by the sum of the lengths of implanted stent (ISNV), and the in-stent percent neointimal volume obstruction (%VO) were evaluated at 6-9 months by means of Optical Coherence Tomography (OCT).

Cardionovum® announces that the HYPER Study results, featuring the innovative RESTORE®  DEB, have been published online in the Minerva Cardiology and Angiology journal, with the article entitled "Procedural and one-year outcomes following drug-eluting stent and drug-coated balloon combination for the treatment of de novo diffuse coronary artery disease: the HYPER Study”.

 

The HYPER is a prospective, multicenter study including patients affected by de novo diffuse CAD treated with a hybrid approach from April 2019 to December 2020, having as primary endpoint the evaluation of the 1-year device-oriented composite endpoint (DoCE, cardiac death, target vessel myocardial infarction and ischemia-driven target lesion revascularization [ID-TLR]).

Dott. Ielasi (Milan, Italy) speaks to Radcliffe at EuroPCR 2023 congress held in Paris (France) about the results of the Hyper Study 2-years Follow-up.

 

In this video interview, Dott. Ielasi summarizes the benefits of RESTORE® paclitaxel eluting balloon and comments the results of the Hyper study at 2 years, putting a focus on the encouraging results of the combined use of modern DES and RESTORE® DEB in the context of de novo diffuse CAD: in detail, results showed a 2-year clinical follow-up available for the vast majority of the patients enrolled (n=105/106, 99%) and a low incidence of Device oriented Composite Endpoint (DoCE) equal to 4.6% at 24 months.

 

In conclusion, even if larger and more robust data from RCTs (vs. full metal jacket PCIs) are needed to confirm the findings, the HYPER study reports very encouraging results in terms of safety and efficacy of the hybrid approach in the treatment of diffuse CAD.

Prof. Matteo Tozzi (Varese, Italy) spoke to Vascular News at Charing Cross 2023 meeting held in London (England) about the variety of vascular access complications and their treatment options.

 

In this video-interview, Prof. Tozzi commented as fantastic the clinical outcomes of Aperto® DCB in his recent analysis, in which more than 600 Aperto® DCB have been used in ArteriousVenous Fistula (AVF) and AVG, including a large number of Central Vein Stenosis (CVS).

Prof. Michael Lichtenberg (Arnsberg, Germany) speaks to Vascular News at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2022 annual meeting in Barcelona (Spain) about the importance on new endovascular strategies, such as Drug-Coated Balloons (DCBs), to improve patency rates in patients with consecutive neointimal hyperplasia in haemodialysis access.

 

In this interview, a particular focus is put on the promising results of APERTO® OTW, our high-pressure paclitaxel releasing DCB, considered as “one of the very promising new technologies” for treating restenosis in dialysis access patients

Bonn, Germany. November 16, 2022 – Data presented at Innovation session today at the CSC 2022 congress demonstrated an equivalent performance of the Xlimus® DES in terms of OCT derived endpoints than the Synergy™ DES, including Neointimal Volume and Neointimal Volume weighted by length at 6 months. Secondary endpoints, including other OCT parameters, such as in-stent Minimum Lumen Area (MLA) and percentage of strut coverage as well as clinical endpoints, showed no significant differences between the two groups in any of the evaluated parameters within the Xlimit RCT.

Upcoming events

Cardionovum® at CIRSE 2024

Cardionovum® is glad to inform that will attend CIRSE 2024.

Location:

CCL – Lisbon Congress Centre
Praça das Industrias 1
1300-307 Lisbon
Portugal

Date: Sep 14, 2024–Sep 18, 2024

Latest events

Cardionovum at GISE 2022

Cardionovum invites you to attend a scientific session:

  • GAP IN KNOWLEDGE:
    Role of drug-coated balloons in de novo lesions

    Dr Alfonso Ielasi - the PI of the Hyper study - will share his findings on the topic of:
    Clinical scenario: “A patient treated with a hybrid DES-DEB strategy”

    Thursday 11st October at 14:30h
    ROOM AMBER 5-6

Location:

Allianz MiCo - Milano Congressi
South Wing
Viale Eginardo - Gate 2
20149 Milano, Italy

You are welcome to visit us at booth #45, 2nd Floor (ALA SUD)

Date: Oct 11, 2022–Oct 14, 2022

Learn more >>

Cardionovum at CIRSE 2022

Cardionovum invites you to visit us at booth #70

Location:

CCIB Conference Center
Plaça de Willy Brandt, 11-14,
08019 Barcelona, Spain
 

Date: Sep 10, 2022–Sep 14, 2022

Cardionovum at Linc 2022

Cardionovum invites you to participate in a scientific session:

  • Pr. Matteo Tozzi will disclose the results of his study:
    Paclitaxel blood concentration after peripheral DCB PTA evaluated by HPLC

    Tuesday 7th June at 14,25h
    Speakers Corner

     

You are welcome to visit us at booth #10

Date: June 06, 2022–June 09, 2022

Location: Trade Fair Leipzig, Hall 2 - Seehausener Allee 1 - 04356 Leipzig, Germany

Learn more >>

go top